RGNX vs VTR · rev $114.4M vs P/E 149, rev $1.73B
Regenxbio Inc (RGNX) versus Ventas Inc (VTR) — a side-by-side from cached financials, not a winner call.
Regenxbio Inc (RGNX) is a biotechnology company listed on US.
Ventas Inc (VTR) is a reit - healthcare facilities company listed on NYSE.
Latest reported RGNX revenue for 2026-06-30 was $114.4M. Net income was -$67.3M. RGNX currently screens at market cap $440.4M.
Latest reported VTR revenue for 2026-06-30 was $1.73B. Net income was $72.2M. Revenue was up 4.4% from 2026-03-31 to 2026-06-30. VTR currently screens at market cap $39.94B and trailing P/E 149.4.
RGNX currently screens at market cap $440.4M. VTR currently screens at market cap $39.94B and trailing P/E 149.4.
Not investment advice. Open the RGNX and VTR stock pages for the full models.
Not investment advice.